2,800 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Robertson Stephens Wealth Management LLC

Robertson Stephens Wealth Management LLC acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 2,800 shares of the biopharmaceutical company’s stock, valued at approximately $1,113,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Root Financial Partners LLC acquired a new position in Alnylam Pharmaceuticals during the third quarter worth $25,000. Salomon & Ludwin LLC acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at $27,000. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at $29,000. Ameriflex Group Inc. acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at $32,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at $36,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $296.11 on Monday. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The firm has a market cap of $39.51 billion, a P/E ratio of 80.90 and a beta of 0.31. Alnylam Pharmaceuticals, Inc. has a 52 week low of $245.96 and a 52 week high of $495.55. The business’s fifty day simple moving average is $320.11 and its 200 day simple moving average is $376.18.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $1.09. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business’s revenue for the quarter was up 96.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.44) earnings per share. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.78 EPS for the current fiscal year.

Analysts Set New Price Targets

ALNY has been the topic of several research reports. Royal Bank Of Canada lowered their target price on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a report on Friday. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Canaccord Genuity Group upped their target price on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Wall Street Zen raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Barclays initiated coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $471.96.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 2,206 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $722,795.90. Following the sale, the executive vice president owned 64,273 shares of the company’s stock, valued at $21,059,048.45. This trade represents a 3.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Pushkal Garg sold 1,775 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $319.74, for a total value of $567,538.50. Following the sale, the executive vice president directly owned 23,406 shares in the company, valued at approximately $7,483,834.44. The trade was a 7.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 38,656 shares of company stock valued at $12,370,696. 0.86% of the stock is owned by company insiders.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 beat driven by Amvuttra — Alnylam reported Q1 EPS of $1.99 and revenue of $1.17B, topping estimates; Amvuttra sales surged ~187% and helped drive 96% year‑over‑year revenue growth. Read More.
• Positive Sentiment: Brokerage support — Several brokerages continue to rate ALNY favorably (consensus around “moderate buy” and H.C. Wainwright remains a buy), which supports upside sentiment over the medium term. Read More.
• Neutral Sentiment: Mixed analyst target moves — Wells Fargo nudged its target slightly higher but kept an “equal weight” stance; RBC trimmed its target marginally but maintains an “outperform” view (still implying sizeable upside). These are tweaks rather than directional shifts. Read More. Read More.
• Neutral Sentiment: Investor materials and commentary available — Full earnings slide deck and call transcript were published (useful for modeling product-level trends and guidance; contributes to re‑rating discussions). Read More.
• Negative Sentiment: Risks and product headwinds — The quarter showed declines in collaborator revenue and Onpattro sales that offset some gains; an outside review highlighted a new regulatory risk and warned the stock could carry a higher risk of significant losses, which likely pressured sentiment. Read More.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.